NR5A2 Antibody (YA9771)
(Synonyms: Nuclear Receptor Subfamily 5 Group A Member 2, LRH-1, FTZ-F1beta, FTZ-F1, HB1F-2, HB1F, B1F2, LRH1, FTF, CYP7A Promoter-Binding Factor, B1F, CPF, B1-Binding Factor, Hepatocyte Transcription Factor Which Activates Enhancer II Of Hepatitis B Virus, Nuclear Receptor Subfamily 5, Group A, Member 2, Fetoprotein-Alpha 1 (AFP) Transcription Factor, Alpha-1-Fetoprotein Transcription Factor, Hepatocytic Transcription Factor HB1F-3, Hepatocytic Transcription Factor, Liver Receptor Homolog-1, Liver Receptor Homolog 1, B1-Binding Factor)NR5A2 Antibody (YA9771) is a Rabbit-derived and non-conjugated IgG Monoclonal, Recombinant antibody, targeting to NR5A2.
-
Host:
Rabbit
-
Isotype:
IgG
-
Application:
WB, FC, ICC/IF
-
Reactivity :
Human, mouse, rat
-
Formulation:
Supplied in PBS (pH 7.4) containing 50% glycerol, 0.05% BSA and 0.02% sodium azide.
-
Conjugation:
Non-conjugated
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
Applications
| Application |
WB
WB: Western Blot
|
FC
FC: Flow Cytometry
|
ICC/IF
ICC/IF: Immunocytochemistry/
Immunofluorescence |
|---|---|---|---|
| Dilution Ratio | 1:1000-5000 | 1:200-2000 | 1:100-1000 |
Product Details
NR5A2 Antibody (YA9771) is a Rabbit-derived and non-conjugated IgG Monoclonal, Recombinant antibody, targeting to NR5A2.
-
Host Rabbit
-
Species ReactivityHuman, mouse, rat
-
Observed Molecular WeightObserved band size: 65 kDa
Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
-
Calculated Molecular Weight Predicted band size: 61 kDa
A synthesized peptide derived from human NR5A2
affinity purified.
Non-conjugated
IgG
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in PBS (pH 7.4) containing 50% glycerol, 0.05% BSA and 0.02% sodium azide.
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
NR5A2 is an Orphan nuclear receptor that binds DNA as a monomer to the 5'-TCAAGGCCA-3' sequence and controls expression of target genes: regulates key biological processes, such as early embryonic development, cholesterol and bile acid synthesis pathways, as well as liver and pancreas morphogenesis. Ligand-binding causes conformational change which causes recruitment of coactivators, promoting target gene activation. The specific ligand is unknown, but specific phospholipids, such as phosphatidylethanolamine, phosphatidylserine, dilauroyl phosphatidylcholine and diundecanoyl phosphatidylcholine can act as ligand in vitro. Acts as a pioneer transcription factor, which unwraps target DNA from histones and elicits local opening of closed chromatin. Plays a central role during preimplantation stages of embryonic development (By similarity). Plays a minor role in zygotic genome activation (ZGA) by regulating a small set of two-cell stage genes (By similarity). Plays a major role in morula development (2-16 cells embryos) by acting as a master regulator at the 8-cell stage, controlling expression of lineage-specifying transcription factors and genes involved in mitosis, telomere maintenance and DNA repair (By similarity). Zygotic NR5A2 binds to both closed and open chromatin with other transcription factors, often at SINE B1/Alu repeats DNA elements, promoting chromatin accessibility at nearby regulatory regions (By similarity). Also involved in the epiblast stage of development and embryonic stem cell pluripotency, by promoting expression of POU5F1/OCT4. Regulates other processes later in development, such as formation of connective tissue in lower jaw and middle ear, neural stem cell differentiation, ovarian follicle development and Sertoli cell differentiation (By similarity). Involved in exocrine pancreas development and acinar cell differentiation (By similarity). Acts as an essential transcriptional regulator of lipid metabolism. Key regulator of cholesterol 7-alpha-hydroxylase gene (CYP7A) expression in liver. Also acts as a negative regulator of inflammation in different organs, such as, liver and pancreas. Protects against intestinal inflammation via its ability to regulate glucocorticoid production (By similarity). Plays an anti-inflammatory role during the hepatic acute phase response by acting as a corepressor: inhibits the hepatic acute phase response by preventing dissociation of the N-Cor corepressor complex. Acts as a regulator of immunity by promoting lymphocyte T-cell development, proliferation and effector functions (By similarity). Also involved in resolution of endoplasmic reticulum stress in the liver (By similarity)[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16].
-
Subcellular Localization
Nucleus; Chromosome
-
Expression
Tissue_Specificity: Abundantly expressed in pancreas, less in liver, very low levels in heart and lung. Expressed in the Hep-G2 cell line. Isoform 1 and isoform 2 seem to be present in fetal and adult liver and Hep-G2 cells. -
Isoforms & Post-Translational Modification
NR5A2 has 4 isoforms, O00482-1: amino acid length is 541, molecular weight is 61331 Da (predicted); O00482-2: amino acid length is 495, molecular weight is 56459 Da (predicted); O00482-3: amino acid length is 369, molecular weight is 42102 Da (predicted); O00482-4: amino acid length is 469, molecular weight is 53657 Da (predicted).
Sumoylated by SUMO1 at Lys-270 during the hepatic acute phase response, leading to promote interaction with GPS2 and prevent N-Cor corepressor complex dissociation. -
Subunit
Monomer; Binds DNA as a monomer.
-
SwissProt ID
-
Synonyms
Nuclear Receptor Subfamily 5 Group A Member 2, LRH-1, FTZ-F1beta, FTZ-F1, HB1F-2, HB1F, B1F2, LRH1, FTF, CYP7A Promoter-Binding Factor, B1F, CPF, B1-Binding Factor, Hepatocyte Transcription Factor Which Activates Enhancer II Of Hepatitis B Virus, Nuclear Receptor Subfamily 5, Group A, Member 2, Fetoprotein-Alpha 1 (AFP) Transcription Factor, Alpha-1-Fetoprotein Transcription Factor, Hepatocytic Transcription Factor HB1F-3, Hepatocytic Transcription Factor, Liver Receptor Homolog-1, Liver Receptor Homolog 1, B1-Binding Factor
Documentation
[1]. Solomon IH, et al. Crystal structure of the human LRH-1 DBD-DNA complex reveals Ftz-F1 domain positioning is required for receptor activity. J Mol Biol. 2005 Dec 16;354(5):1091-102. [Content Brief]
[2]. Burendahl S, et al. Molecular dynamics simulations of human LRH-1: the impact of ligand binding in a constitutively active nuclear receptor. Biochemistry. 2008 May 6;47(18):5205-15. [Content Brief]
[3]. Lee JM, et al. A nuclear-receptor-dependent phosphatidylcholine pathway with antidiabetic effects. Nature. 2011 May 25;474(7352):506-10. [Content Brief]
[4]. Seacrist CD, et al. Integrated Structural Modeling of Full-Length LRH-1 Reveals Inter-domain Interactions Contribute to Receptor Structure and Function. Structure. 2020 Jul 7;28(7):830-846.e9. [Content Brief]
[5]. Kobayashi W, et al. Nucleosome-bound NR5A2 structure reveals pioneer factor mechanism by DNA minor groove anchor competition. Nat Struct Mol Biol. 2024 May;31(5):757-766. [Content Brief]
[6]. Li M, et al. Cloning and characterization of a novel human hepatocyte transcription factor, hB1F, which binds and activates enhancer II of hepatitis B virus. J Biol Chem. 1998 Oct 30;273(44):29022-31. [Content Brief]
[7]. Krylova IN, et al. Structural analyses reveal phosphatidyl inositols as ligands for the NR5 orphan receptors SF-1 and LRH-1. Cell. 2005 Feb 11;120(3):343-55. [Content Brief]
[8]. Ortlund EA, et al. Modulation of human nuclear receptor LRH-1 activity by phospholipids and SHP. Nat Struct Mol Biol. 2005 Apr;12(4):357-63. [Content Brief]
[9]. Wang W, et al. The crystal structures of human steroidogenic factor-1 and liver receptor homologue-1. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7505-10. [Content Brief]
[10]. Musille PM, et al. Antidiabetic phospholipid-nuclear receptor complex reveals the mechanism for phospholipid-driven gene regulation. Nat Struct Mol Biol. 2012 Apr 15;19(5):532-S2. [Content Brief]
[11]. Musille PM, et al. Divergent sequence tunes ligand sensitivity in phospholipid-regulated hormone receptors. J Biol Chem. 2013 Jul 12;288(28):20702-12. [Content Brief]
[12]. Sablin EP, et al. Structure of Liver Receptor Homolog-1 (NR5A2) with PIP3 hormone bound in the ligand binding pocket. J Struct Biol. 2015 Dec;192(3):342-348. [Content Brief]
[13]. Musille PM, et al. Unexpected Allosteric Network Contributes to LRH-1 Co-regulator Selectivity. J Biol Chem. 2016 Jan 15;291(3):1411-26. [Content Brief]
[14]. Weikum ER, et al. A Structural Investigation into Oct4 Regulation by Orphan Nuclear Receptors, Germ Cell Nuclear Factor (GCNF), and Liver Receptor Homolog-1 (LRH-1). J Mol Biol. 2016 Dec 4;428(24 Pt B):4981-4992. [Content Brief]
[15]. Venteclef N, et al. GPS2-dependent corepressor/SUMO pathways govern anti-inflammatory actions of LRH-1 and LXRbeta in the hepatic acute phase response. Genes Dev. 2010 Feb 15;24(4):381-95. [Content Brief]
[16]. Nitta M, et al. CPF: an orphan nuclear receptor that regulates liver-specific expression of the human cholesterol 7alpha-hydroxylase gene. Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6660-5. [Content Brief]
Powered by Bioz
